Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial

Fig. 3

Overall survival and progression-free survival on Kaplan–Meier analysis. (a) There were no significant differences in the OS and PFS between the two treatment arms. That is, the median OS was 360 days (95 % CI: 285–482) in the BP arm and 305 days (95 % CI: 232–343) in the EP arm (Log-Rank p = 0.210). (b) The median PFS was 190 days (95 % CI: 148-219) in the BP arm and 172 days (95 % CI: 144–195) in the EP arm (Log-Rank p = 0.369)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us